Your browser doesn't support javascript.
loading
The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia.
Gunn, Jack; O'Keefe, Daniel; Draper, Bridget Louise; Djordjevic, Filip; Ryan, Kathleen; Kerr, Phoebe; Elsum, Imogen; Gold, Judy; Layton, Chloe; Chan, Kico; Dietze, Paul; Higgs, Peter; Doyle, Joseph; Stoové, Mark A; Hellard, Margaret; Pedrana, Alisa.
Affiliation
  • Gunn J; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia jack.gunn@burnet.edu.au.
  • O'Keefe D; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Draper BL; School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
  • Djordjevic F; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Ryan K; School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
  • Kerr P; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Elsum I; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Gold J; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Layton C; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Chan K; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Dietze P; School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
  • Higgs P; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Doyle J; Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • Stoové MA; School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
  • Hellard M; National Drug Research Institute, Curtin University, Perth, Western Australia, Australia.
  • Pedrana A; Behaviours and Health Risks Program, Burnet Institute, Melbourne, Victoria, Australia.
BMJ Open ; 13(7): e071665, 2023 07 03.
Article in En | MEDLINE | ID: mdl-37400235
ABSTRACT

OBJECTIVES:

Direct-acting antivirals provide an opportunity to eliminate hepatitis C virus (HCV) as a public health threat in Australia, yet barriers to care remain. In this study, we use baseline data from a longitudinal cohort of people who inject drugs to understand differences in participant characteristics and explore experiences of stigma, health service utilisation and health literacy between three care cascade groups.

DESIGN:

Cross-sectional.

SETTING:

Community and private primary healthcare services in Melbourne, Australia.

PARTICIPANTS:

Participants completed baseline surveys between 19 September 2018 and 15 December 2020. We recruited 288 participants; the median age was 42 years (IQR 37-49 years) and 198 (69%) were male. At baseline, 103 (36%) self-reported being 'not engaged in testing', 127 (44%) had HCV RNA positivity but were 'not engaged in treatment' and 58 (20%) were 'engaged in HCV treatment'. OUTCOME

MEASURES:

Descriptive statistics were used to present the baseline demographics, health service utilisation and experiences of stigma data. We explored differences in these scales between participant demographics using χ2 test or fisher's exact tests, and differences between health literacy scores using one-way analysis of variance tests.

RESULTS:

A majority were in regular contact with multiple health services, and most had previously been identified as at-risk of HCV. In the 12 months preceding baseline, 70% reported any experiences of stigma related to injecting drug use. Assessment of health literacy data identified gaps for those 'not engaged in testing' and 'not engaged in treatment' across two relevant domains 'ability to appraise health information' and 'ability to actively engage with healthcare providers'.

CONCLUSION:

In eliminate hepatitis C experience, lower HCV testing and treatment may be explained by experiences of stigmatisation or gaps in health literacy. Enhanced interventions targeting people who inject drugs to promote HCV care are needed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Abuse, Intravenous / Hepatitis C / Hepatitis C, Chronic / Drug Users Type of study: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Oceania Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Substance Abuse, Intravenous / Hepatitis C / Hepatitis C, Chronic / Drug Users Type of study: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Oceania Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: Australia